Rivaroxaban and Aspirin Dual Therapy for Peripheral Artery Disease
A meta-analysis of COMPASS and VOYAGER compared low-dose rivaroxaban and aspirin vs aspirin alone across a broad spectrum of patients with PAD.
Peripheral Artery Disease
Peripheral Artery Disease Associated With Increased Abdominal Aortic Aneurysm Risk
A prospective, cross-sectional study examined the relationship between symptomatic and asymptomatic PAD with risk for abdominal aortic aneurysm.
Hybrid First-Line Treatment Approach for Chronic Limb-Threatening Ischemia
Investigators evaluated outcomes of a first-line hybrid approach in patients with chronic limb-threatening ischemia to determine possible predictors of loss of primary patency and limb clinical improvement.
Rivaroxaban Approval Expands to Symptomatic PAD After Revascularization
The approval was based on data from the phase 3 VOYAGER PAD study.
Optimizing Lipid Control for Lower Extremity Peripheral Artery Disease
This review examines the current guidance and issues related to lipid optimization of patients with peripheral arterial disease (PAD).
ALI Risk High After Stent Graft Thrombosis Even With Low Amputation Risk
The researchers’ goal was to determine the clinical impact of stent graft thrombosis and its prognosis.
Rivaroxaban Plus Aspirin Further Reduced Recurrent Ischemic Events Post-LE Revascularization
Researchers found an additive benefit with rivaroxaban in combination with aspirin in terms of event reduction.
Older Age, Diabetes Duration, and CAD Are Leading Risk Factors for PAD in Patients With T2DM
Researchers report the results of a systematic review assessing risk factors for peripheral artery disease in populations with type 2 diabetes.
Safety of Drug-Coated Devices for Femoropopliteal Revascularization
SAFE-PAD evaluated the real-world safety of femoropopliteal artery revascularization using drug-coated vs non-drug-coated devices.
E/e’ Ratio 15 or Higher Ups Risk for 5-Year Mortality for Patients With PTA for PAD
Investigators sought to determine whether elevated E/e’ ratio is an independent predictor for mortality at 5 years among patients undergoing percutaneous transluminal angioplasty for peripheral artery disease.
- Loading...
Loading...
Next post in Vascular Medicine
Loading... 
Loading...